Analysts Predict FHLC Will Hit $78
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Source: NASDAQ.COM
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 47.500
Low
66.00
Averages
76.00
High
86.00
Current: 47.500
Low
66.00
Averages
76.00
High
86.00
About PBH
Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells and distributes over-the-counter (OTC) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Breathe Right nasal strips, Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, highlighting challenges in cost management that may affect profitability.
- Sales Missed Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following this news, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, suggesting effective cost control but insufficient improvement in profitability amidst declining revenues.
- Sales Miss: CEO Ron Lombardi revealed during the earnings call that Clear Eyes sales fell short of expectations due to shipment delays and production shutdowns, which may exacerbate market concerns regarding the company's future performance.
- Significant Stock Drop: Following the earnings report, Prestige's stock price plummeted by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted total gross margin stood at 55.6%, nearly unchanged from 55.8% the previous year, suggesting a lack of improvement in profitability that may affect shareholder return expectations.
- Sales Missed Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to shipment delays and production shutdowns, directly impacting revenue performance and raising concerns about the company's future outlook.
- Significant Stock Price Drop: Following the disappointing earnings report, Prestige's stock price plummeted by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's prospects.
See More
Prestige Consumer Healthcare Under Investigation for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Prestige Consumer Healthcare Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Declining Financial Performance: Prestige reported on May 13, 2026, that its fiscal 2026 revenues decreased by 4.5% year-over-year, with an adjusted gross margin of 55.6% remaining flat compared to the previous year, indicating significant market challenges.
- Stock Price Reaction: Following the earnings report, Prestige's shares fell by 11.35% the next day, reflecting heightened investor concerns about the company's financial health, which could impact future financing and investor confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for free consultations, highlighting the importance of protecting investor rights and the necessity for legal support in such situations.
See More
Prestige Consumer Healthcare Q4 Earnings Miss Expectations, Shares Plummet
- Earnings Miss: Prestige Consumer Healthcare reported an adjusted EPS of $1.23 for Q4 fiscal 2026, significantly below the expected $1.39, resulting in a sharp decline in share price and highlighting ongoing supply chain issues.
- Revenue Shortfall: The company generated $281.6 million in revenue for the quarter, falling short of analyst forecasts, indicating a severe imbalance between product supply and market demand that could impact future market share.
- Management Promises Unfulfilled: Despite CEO Ron Lombardi's assurances of continued supply chain improvements in Q4, the actual results did not meet expectations, leading to diminished investor confidence and potential legal scrutiny.
- Investigation Launched: Levi & Korsinsky LLP has initiated an investigation into Prestige Consumer Healthcare regarding potential misstatements about supply chain risks prior to the earnings miss, which may expose more investors to losses.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, suggesting challenges in cost management that may impact profitability and shareholder returns.
- Sales Miss Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following the earnings announcement, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, highlighting challenges in cost management that may affect profitability.
- Sales Missed Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following this news, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, suggesting effective cost control but insufficient improvement in profitability amidst declining revenues.
- Sales Miss: CEO Ron Lombardi revealed during the earnings call that Clear Eyes sales fell short of expectations due to shipment delays and production shutdowns, which may exacerbate market concerns regarding the company's future performance.
- Significant Stock Drop: Following the earnings report, Prestige's stock price plummeted by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted total gross margin stood at 55.6%, nearly unchanged from 55.8% the previous year, suggesting a lack of improvement in profitability that may affect shareholder return expectations.
- Sales Missed Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to shipment delays and production shutdowns, directly impacting revenue performance and raising concerns about the company's future outlook.
- Significant Stock Price Drop: Following the disappointing earnings report, Prestige's stock price plummeted by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's prospects.
See More
Prestige Consumer Healthcare Under Investigation for Securities Violations
- Investigation Launched: The Schall Law Firm has announced an investigation into Prestige Consumer Healthcare Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Declining Financial Performance: Prestige reported on May 13, 2026, that its fiscal 2026 revenues decreased by 4.5% year-over-year, with an adjusted gross margin of 55.6% remaining flat compared to the previous year, indicating significant market challenges.
- Stock Price Reaction: Following the earnings report, Prestige's shares fell by 11.35% the next day, reflecting heightened investor concerns about the company's financial health, which could impact future financing and investor confidence.
- Investor Rights Protection: The Schall Law Firm encourages affected shareholders to reach out for free consultations, highlighting the importance of protecting investor rights and the necessity for legal support in such situations.
See More
Prestige Consumer Healthcare Q4 Earnings Miss Expectations, Shares Plummet
- Earnings Miss: Prestige Consumer Healthcare reported an adjusted EPS of $1.23 for Q4 fiscal 2026, significantly below the expected $1.39, resulting in a sharp decline in share price and highlighting ongoing supply chain issues.
- Revenue Shortfall: The company generated $281.6 million in revenue for the quarter, falling short of analyst forecasts, indicating a severe imbalance between product supply and market demand that could impact future market share.
- Management Promises Unfulfilled: Despite CEO Ron Lombardi's assurances of continued supply chain improvements in Q4, the actual results did not meet expectations, leading to diminished investor confidence and potential legal scrutiny.
- Investigation Launched: Levi & Korsinsky LLP has initiated an investigation into Prestige Consumer Healthcare regarding potential misstatements about supply chain risks prior to the earnings miss, which may expose more investors to losses.
See More
Pomerantz Investigates Prestige Consumer Healthcare for Securities Fraud
- Declining Financial Performance: Prestige Consumer Healthcare reported a 4.5% year-over-year revenue decline for fiscal 2026, indicating significant market pressure that could undermine investor confidence moving forward.
- Flat Gross Margin: The company's adjusted gross margin for the year was 55.6%, nearly unchanged from 55.8% the previous year, suggesting challenges in cost management that may impact profitability and shareholder returns.
- Sales Miss Expectations: CEO Ron Lombardi noted during the earnings call that Clear Eyes sales fell short due to delayed shipments and production shutdowns, raising concerns about the company's future performance in the market.
- Significant Stock Price Drop: Following the earnings announcement, Prestige's stock price fell by $5.88, or 11.35%, closing at $45.93 per share on May 14, 2026, reflecting a pessimistic sentiment among investors regarding the company's outlook.
See More
